The stock price of Cg Oncology Inc (NASDAQ: CGON) has plunged by -0.04 when compared to previous closing price of 24.18, but the company has seen a 8.19% gain in its stock price over the last five trading sessions. zacks.com reported 2025-05-13 that CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.36 per share a year ago.
Is It Worth Investing in Cg Oncology Inc (NASDAQ: CGON) Right Now?
The 36-month beta value for CGON is also noteworthy at 0.77. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CGON is 46.04M, and at present, short sellers hold a 24.38% of that float. The average trading volume of CGON on May 15, 2025 was 1.31M shares.
CGON’s Market Performance
CGON stock saw an increase of 8.19% in the past week, with a monthly gain of 20.49% and a quarterly increase of -13.68%. The volatility ratio for the week is 7.60%, and the volatility levels for the last 30 days are 8.48% for Cg Oncology Inc (CGON). The simple moving average for the last 20 days is 1.00% for CGON stock, with a simple moving average of -21.55% for the last 200 days.
Analysts’ Opinion of CGON
Many brokerage firms have already submitted their reports for CGON stocks, with JP Morgan repeating the rating for CGON by listing it as a “Overweight.” The predicted price for CGON in the upcoming period, according to JP Morgan is $41 based on the research report published on May 02, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see CGON reach a price target of $23. The rating they have provided for CGON stocks is “Sector Perform” according to the report published on April 16th, 2025.
CGON Trading at 0.87% from the 50-Day Moving Average
After a stumble in the market that brought CGON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.28% of loss for the given period.
Volatility was left at 8.48%, however, over the last 30 days, the volatility rate increased by 7.60%, as shares surge +20.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.54% lower at present.
During the last 5 trading sessions, CGON rose by +8.19%, which changed the moving average for the period of 200-days by -26.91% in comparison to the 20-day moving average, which settled at $23.93. In addition, Cg Oncology Inc saw -15.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGON starting from POST LEONARD E, who sale 1,000 shares at the price of $30.76 back on Apr 28 ’25. After this action, POST LEONARD E now owns 0 shares of Cg Oncology Inc, valued at $30,760 using the latest closing price.
POST LEONARD E, the Director of Cg Oncology Inc, sale 1,000 shares at $28.00 during a trade that took place back on Mar 17 ’25, which means that POST LEONARD E is holding 0 shares at $28,000 based on the most recent closing price.
Stock Fundamentals for CGON
Current profitability levels for the company are sitting at:
- -220.33 for the present operating margin
- 0.99 for the gross margin
The net margin for Cg Oncology Inc stands at -116.57. The total capital return value is set at -0.19. Equity return is now at value -16.57, with -16.15 for asset returns.
Based on Cg Oncology Inc (CGON), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -79.13.
Currently, EBITDA for the company is -114.67 million with net debt to EBITDA at 0.3. When we switch over and look at the enterprise to sales, we see a ratio of 2953.85. The receivables turnover for the company is 1.77for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 30.97.
Conclusion
In summary, Cg Oncology Inc (CGON) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
